Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
-
December 23, 2024
Fujirebio and Eisai Enter into Memorandum of Understanding for
Joint Research and Social Implementation of Blood-based Biomarkers
in the Field of Neurodegenerative Diseases
-
December 11, 2024
“URECE®” (DOTINURAD) APPROVED IN CHINA FOR GOUT PATIENTS WITH HYPERURICEMIA
-
December 5, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico
-
November 29, 2024
Eisai Announces Completion of Cancellation of Treasury Shares
Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act
-
November 28, 2024
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea
-
November 26, 2024
EISAI SIGNS RESEARCH COLLABORATION AGREEMENT WITH THE NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY TO INITIATE APOLIPOPROTEIN E GENETIC TESTING IN THE “AD-DMT REGISTRY” IN JAPAN
-
November 20, 2024
ROZEBALAMIN® FOR INJECTION 25 MG (MECOBALAMIN) FOR AMYOTROPHIC LATERAL SCLEROSIS LAUNCHED IN JAPAN
-
November 20, 2024
ANTICANCER AGENT “TASFYGO® TABLETS 35mg” (TASURGRATINIB SUCCINATE) LAUNCHED IN JAPAN FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSION OR REARRANGEMENTS
-
November 15, 2024
NATIONWIDE TV COMMERCIAL LAUNCHED IN JAPAN TO RAISE AWARENESS ABOUT MCI (MILD COGNITIVE IMPAIRMENT)
-
November 15, 2024
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
-
November 5, 2024
Eisai’s Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED’s ‘Strengthening Program for Pharmaceutical Startup Ecosystem’
-
November 1, 2024
Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
-
October 31, 2024
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration-
-Patient and caregiver perspectives on five-year treatment with lecanemab-
-Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD-
-
October 31, 2024
EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD)
Eisai Initiates Phase II Clinical Study on Sporadic Early Alzheimer's Disease
-
October 30, 2024
REVENUE OF LEQEMBI® (PRELIMINARY BASIS)
-
October 24, 2024
EISAI TO PRESENT UPDATED DUAL-ACTING LECANEMAB DATA, RESEARCH ON BLOOD BIOMARKERS FOR PREDICTING PRESENCE OF AMYLOID IN THE BRAIN AND NEW FINDINGS ON THE ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS FOR ALZHEIMER'S
-
October 17, 2024
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Demonstrating the Utility of Blood Biomarkers in Predicting Amyloid Beta Accumulation in the Brain
-
October 17, 2024
UPDATE ON REGULATORY REVIEW OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN AUSTRALIA
-
October 16, 2024
AMYOTROPHIC LATERAL SCLEROSIS TREATMENT “ROZEBALAMIN® FOR INJECTION 25 MG” RECEIVES THE GOOD DESIGN AWARD 2024 FOR LIGHT-PROOF VIAL PACKAGING
-
October 8, 2024
“URECE® TABLETS” (DOTINURAD) APPROVED IN THAILAND FOR GOUT AND HYPERURICEMIA
-
October 4, 2024
Eisai Announces Status and Completion of Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
October 2, 2024
EISAI COMMENCES BUSINESS ACTIVITIES AT NEW PHARMA SALES SUBSIDIARY IN SAUDI ARABIA
-
October 1, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
September 24, 2024
ROZEBALAMIN® FOR INJECTION 25 MG (MECOBALAMIN) APPROVED IN JAPAN FOR AMYOTROPHIC LATERAL SCLEROSIS
-
September 24, 2024
ANTICANCER AGENT “TASFYGO® TABLETS 35mg” (TASURGRATINIB SUCCINATE)
APPROVED IN JAPAN FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSIONS OR REARRANGEMENTS
-
September 17, 2024
RELEASE OF DEMENTIA DISEASE AWARENESS VIDEO FOR WORLD ALZHEIMER’S MONTH
“TODAY FOR TOMORROW”: A DOCUMENTARY OF SIX MONTHS FOLLOWING THE CURRENT STATE OF DEMENTIA
“LEARNING HELPS US TO BE KIND”
-
September 17, 2024
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
In the Phase 3 LEAP-012 trial, LENVIMA plus KEYTRUDA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone
Late-breaking first interim analysis results are being presented during a Presidential Symposium session at the European Society for Medical Oncology Congress 2024
-
September 12, 2024
Investigator-initiated clinical studies to be launched following confirmation of tumor shrinkage induced by the targeted protein degrader E7820 using J-PDX (Japanese cancer patient-derived tissue transplantation models)
Aiming to establish a drug discovery and development system that accelerates the development of new anticancer drugs
-
September 5, 2024
EISAI ACCELERATES PROGRESS IN ONCOLOGY RESEARCH WITH NEW DATA AT ESMO CONGRESS 2024
-
September 2, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
August 27, 2024
RELEASE OF INSOMNIA AWARENESS VIDEO FOR JAPAN’S AUTUMN SLEEP HEALTH WEEKS
-
August 22, 2024
Leqembi® (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain
In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)* heterozygotes or non-carriers
Great Britain becomes the first country in Europe to authorize the medicine, which targets an underlying cause of AD1
-
August 14, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates
-
August 6, 2024
Update Regarding the Regulatory Status of LEQEMBI® Subcutaneous Formulation
-
August 1, 2024
REVENUE OF LEQEMBI® (PRELIMINARY BASIS)
-
August 1, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
July 31, 2024
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at AAIC 2024
- 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
- Clinical Data and Biomarkers Show Alzheimer’s Disease Does Not Stop Progressing After Plaque Clearance. Lecanemab’s Dual Action Supports Neuronal Function by Clearing Highly Toxic Protofibrils that Continue to Cause Neuronal Injury and Death After Rapid Plaque Clearance
- Lecanemab Slows Tau Spread Across All Brain Regions
-
July 26, 2024
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
-
July 24, 2024
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
-
July 23, 2024
EISAI TO PRESENT DUAL-ACTING LECANEMAB THREE YEAR EFFICACY AND SAFETY DATA AND DISCUSS LONG-TERM OUTCOMES OF CONTINUED TREATMENT AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2024
Latest findings from Eisai’s robust Alzheimer’s disease (AD) pipeline will be shared, including the importance of continued treatment of AD, which is a progressive neurodegenerative disease that begins before plaque deposition and continues after plaque removal
-
July 16, 2024
EISAI ENTERS INTO LICENSE AGREEMENT FOR FOSRAVUCONAZOLE IN ASIA/OCEANIA WITH SATO PHARMA
-
July 12, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel
-
July 11, 2024
EISAI LISTED FOR 23RD CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES,
AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
July 11, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong
-
July 1, 2024
EISAI ANNOUNCES MOVE TO SOLO DEVELOPMENT AND COMMERCIALIZATION OF FARLETUZUMAB ECTERIBULIN (FZEC) ANTIBODY DRUG CONJUGATE (ADC)
Strategic collaboration with Bristol Myers Squibb ended
-
July 1, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
June 28, 2024
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
China is the Third Country to Launch LEQEMBI Following the United States and Japan
-
June 27, 2024
Position and Policy Regarding Reduction of the Investment Unit of the Company's Shares
-
June 21, 2024
EISAI CONTINUES CONTRACT FOR FY2024 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY
ACHIEVEMENT OF OUTCOME INDICATORS IN FY2023 PAY FOR SUCCESS CONTRACT
-
June 14, 2024
Eisai Announces Appointments of Directors and Corporate Officers
-
June 10, 2024
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
-
June 3, 2024
EISAI NAMED TO LIST OF THE TIME 100 MOST INFLUENTIAL COMPANIES
-
June 3, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
June 3, 2024
EISAI STRENGTHENS VENTURE INVESTMENT BUSINESS AIMED AT ACCELERATING DRUG DISCOVERY INNOVATION AND ESTABLISHMENT OF ECOSYSTEM PLATFORM
-
May 27, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea
-
May 23, 2024
EISAI SHOWCASES ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2024
-
May 22, 2024
METOJECT® SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR LAUNCHED IN JAPAN
-
May 15, 2024
Eisai Announces Acquisition of Own Shares and Cancellation of Treasury Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act
-
May 15, 2024
Notice of Nominees for Directors and Corporate Officers
-
May 15, 2024
Notice Concerning Appointment of New Representative Officer
-
May 15, 2024
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
-
May 13, 2024
ANTIEPILEPTIC DRUG FYCOMPA® APPROVED IN CHINA FOR ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
-
April 24, 2024
REVENUE OF LEQEMBI® (PRELIMINARY BASIS)
-
April 17, 2024
RESEARCH ON TREATMENTS FOR ALZHEIMER’S DISEASE BASED ON ITS PATHOLOGICAL MECHANISMS RECIEVES AWARD FOR SCIENCE AND TECHNOLOGY (RESEARCH CATEGORY), AS A PART OF FY2024 COMMENDATION FOR SCIENCE AND TECHNOLOGY BY MEXT
-
April 17, 2024
ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION LAUNCHED IN JAPAN
ADDRESSING MEDICAL NEEDS FOR PATIENTS WHO CANNOT TAKE THE MEDICATION ORALLY
-
April 11, 2024
EISAI SUPPORTS RELIEF EFFORTS FOR THE EARTHQUAKE OF THE EAST COAST OF TAIWAN
-
April 2, 2024
FRENCH SALES SUBSIDIARY EISAI S.A.S. TO DIVEST RIGHTS FOR LOXAPAC® AND PARKINANE® LP TO CNX THERAPEUTICS
-
April 1, 2024
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA
-
March 29, 2024
EISAI TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN JAPAN TO KAKEN PHARMACEUTICAL
-
March 28, 2024
EISAI’S BRAIN HEALTH SELF-CHECK TOOL “NOUKNOW®” IS CERTIFIED AS “ME-BYO BRAND” BY KANAGAWA PREFECTURE
-
March 28, 2024
DISCOVERY RESEARCH ON DUAL OREXIN RECEPTOR ANTAGONIST LEMBOREXANT HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 2024
-
March 25, 2024
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
-
March 22, 2024
DELIBERATIONS AT THE CHMP REGARDING THE MARKETING AUTHORIZATION APPLICATION IN THE EU FOR LECANEMAB HAVE BEEN RESCHEDULED DUE TO PROCEDURAL REASONS AT THE EUROPEAN MEDICINES AGENCY
-
March 21, 2024
Lifenet and Eisai Co-Develop Dementia Insurance “be”
Supporting early detection and treatment of dementia and mild cognitive impairment (MCI)
-
March 21, 2024
EISAI SELECTED AS A NADESHIKO BRAND 2024 AS A LISTED COMPANY EXCELLING IN PROMOTION OF WOMEN IN THE WORKPLACE
-
March 6, 2024
EISAI INVESTS IN C2N TO SUPPORT SIMPLIFYING THE DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE TO BETTER SERVE PATIENTS
-
February 29, 2024
EISAI TO PRESENT DATA ON LECANEMAB AND OTHER ALZHEIMER’S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING
-
February 21, 2024
EISAI TO BOOST INITIATIVES ON GREENHOUSE GAS REDUCTION,AIMING TO ACHIEVE NET ZERO BY 2050
PARTICIPATION IN JCI RACE TO ZERO CIRCLE AND APPROVAL FOR SBT 1.5°C TARGET
-
February 20, 2024
EISAI SELECTED FOR “HUMAN CAPITAL LEADERS 2023” AND “HUMAN CAPITAL MANAGEMENT GOLD QUALITY”, RECOGNIZED AS COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES
-
February 15, 2024
METOJECT® SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR APPROVED IN JAPAN
-
February 1, 2024
EISAI COMMENCES FULLY-FLEDGED BUSINESS ACTIVITIES AT PHARMA SALES SUBSIDIARY IN SOUTH AFRICA
COMMENCEMENT OF DIRECT SALES OPERATIONS IN AFRICA, AND ESTABLISHMENT OF BRANCH OFFICE IN KENYA
-
January 26, 2024
EISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRAHIGH-DOSE FORMULATION IN JAPAN FOR THE INDICATION OF AMYOTROPHIC LATERAL SCLEROSIS
-
January 18, 2024
ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION APPROVED IN JAPAN
ADDRESSING MEDICAL NEEDS FOR TREATMENT THROUGH A NON-ORAL ADMINISTRATION ROUTE
-
January 17, 2024
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE EIGHTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 16, 2024
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024
-
January 11, 2024
THE SCIENTIFIC ADVISORY GROUP (SAG) TO CONVENE TO DISCUSS THE MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB IN THE EU
-
January 9, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China
China is the Third Country to Approve LEQEMBI Following the United States and Japan
-
January 5, 2024
EISAI SUPPORTS RELIEF EFFORTS FOR THE NOTO PENINSULA EARTHQUAKE OF 2024 IN JAPAN
